

3 Mahatma Gandhi Marg, Gandhi Nagar Mod Tonk Road, Jaipur (Raj.) Ph.: 0141-2710661

www.aakritilabs.com CIN NO.: U85195RJ2004PTC019563

Name

: Mrs. AMRITA SINGH

Age/Gender: 47 Y 7 M 15 D/Female

Patient ID : 012402090021

BarcodeNo :10114315

Referred By: Self

Registration No: 42768

Registered

: 09/Feb/2024 09:12AM

Analysed

: 09/Feb/2024 03:54PM

Reported

: 09/Feb/2024 03:54PM

Panel

: MEDI WHEEL (ARCOFEMI

HEALTHCARE LTD)

DIGITAL X-RAY CHEST PA VIEW

Soft tissue shadow and bony cages are normal.

Trachea is central.

Bilateral lung field and both CP angle are clear.

Domes of diaphragm are normally placed.

Transverse diameter of heart appears with normal limits.

IMPRESSION:- NO OBVIOUS ABNORMALITY DETECTED.

*** End Of Report ***

Page 1 of



Dr. ARean M.B.B.S., D.M.R.D.



Aakriti Labs

3 Mahatma Gandhi Marg, Gandhi Nagar Mod Tonk Road, Jaipur (Raj.) Ph.: 0141-2710661

www.aakritilabs.com

CIN NO.: U85195RJ2004PTC019563

NAME	MS AMRITA SINGH	AGE	47Y	SEX	FEMALE
REF BY	MEDI WHEEL	DATE	09/02/2024	REG NO	- Contract of the Contract of

ECHOCARDIOGRAM REPORT

WINDOW- PO	OR/ADEQUATE,	GOODVALVE
------------	--------------	-----------

MITRAL NO		NORMAL	AL TRICUSPID N		NORMA	VORMAL		
AORTIC		NORMAL		PULMONARY		NORMA	Participated in Contract of the Contract of th	
2D/M-MOD								
IVSD mm	8.5		IVSS mm	12.2	AORTA	mm	21.6	
LVID mm	40.6		LVIS mm	24.4	LA mm	200110	28.1	
LVPWD mm	8.5		LVPWS mm	14.2	EF%		60%	
CHAMBERS				hi-nii-			100000	
LA		NOR	RMAL	RA		NOR	MAL	
LV		NOF	MAL	RV			MAL	
PERICARDIUM		NOF	MAL			-	April 10 miles	
DOPPLER STUD	DY MITRA							
PEAK VELOCITY	/ m/s E/A	1.27	/0.78	PEAK GRAD	PEAK GRADIANT MmHg			
MEAN VELOCIT	TY m/s		100	The second second	DIANT MmHg			
MVA cm2 (PLA	NITMETER	(Y)		MVA cm2 (the second second second second second			
MR				-				
AORTIC						_		
PEAK VELOCITY	m/s	1.23	is a second	PEAK GRAD	DIANT MmHg	_		
MEAN VELOCITY m/s				The second secon	MEAN GRADIANT MmHg			
AR			-		STATE OF THE PERSON NAMED IN COLUMN 1			
TRICUSPID		-		11				
PEAK VELOCITY	m/s	0.53	MALE	PEAK GRAD	NANT MmHg	1		
MEAN VELOCIT	Y m/s		440	the state of the s	DIANT MmHg			
					P			

PASP mmHg

RVEDP mmHg

PEAK GRADIANT MmHg

MEAN GRADIANT MmHg

IMPRESSION

PEAK VELOCITY m/s

MEAN VELOCITY m/s

PULMONARY

TR

NORMAL LV SYSTOLIC & DIASTOLIC FUNCTION


0.96

- NO RWMA LVEF 60%
- NORMAL RV FUNCTION
- NORMAL CHAMBER DIMENSIONS
- NORMAL VALVULAR ECHO
- INTACT IAS / IVS
- NO THROMBUS, NO VEGETATION, NORMAL PERICARDIUM.
- IVC NORMAL

CONCLUSION: FAIR LV FUNCTION.

Cardiologist







akriti Lahs

3 Mahatma Gandhi Marg, Gandhi Nagar Mod Tonk Road, Jaipur (Raj.) Ph.: 0141-2710661 www.aakritilabs.com

CIN NO.: U85195RJ2004PTC019563

Name : Mrs. AMRITA SINGH

Age/Gender: 47 Y 7 M 15 D/Female

Patient ID : 012402090021

BarcodeNo:10114315

Referred By: Self

Registration No: 42768

Registered

: 09/Feb/2024 09:12AM

Analysed

: 09/Feb/2024 12:22PM

Reported

: 09/Feb/2024 12:22PM

Panel

: MEDI WHEEL (ARCOFEMI

HEALTHCARE LTD)

USG: WHOLE ABDOMEN (Female)

LIVER : Is normal in size, shape and echogenecity.

The IHBR and hepatic radicals are not dilated.

No evidence of focal echopoor/echorich lesion seen. Portal vein diameter and Common bile duct normal in size

GALL

: Is normal in size, shape and echotexture. Walls are smooth and

BLADDER regular with normal thickness. There is no evidence of cholelithiasis.

PANCREAS: Is normal in size shape and echotexture. Pancreatic duct is not dilated. SPLEEN : Is normal in size, shape and echogenecity. Spleenic hillum is not dilated.

KIDNEYS : Bilateral Kidneys are normal in size, shape and echotexture.

corticomedullary differentiation is fair and ratio appears normal.

Petvi calyceal system is normal. No evidence of hydronephrosis/ nephrolithiasis.

URINARY : Bladder walls are smooth, regular and normal thickness.

BLADDER: No evidence of mass or stone in bladder lumen.

UTERUS : Uterus is not visualized. H/o Hysterectomy.

28 x 15 mm size cystic lesion seen in right ovary

SPECIFIC: No evidence of retroperitoneal mass or free fluid seen in peritoneal cavity. NO evidence of lymphadenopathy or mass lesion in retroperitoneum,

Visualized bowel loop appear normal. Great vessels appear normal.

IMPRESSION: Ultra Sonography findings are suggestive of: NORMAL STUDY.

*** End Of Report ***

Page 1 of

Dr. Neera Mehta M.B.B.S., D.M.R.D. RMCNO.005807/14853





PATIENT NAME: MRS AMRITA SINGH	AGE: 47 Yrs.
REF. by: MEDIWHEEL	DATE: 09/02/2024

Ultrasonography report: Breast and Axilla

Findings:

Right Breast:-

Skin, subcutaneous tissue and retroareolar region is normal.

Fibroglandular tissue shows normal architecture and echotexture.

Pre and retromammary regions are unremarkable.

No obvious cyst, mass or architectural distortion visualized.

Axillary lymphnodes are not significantly enlarged and their hilar shadows are preserved.

Left Breast:-

Skin, subcutaneous tissue and retroarcolar region is normal.

Fibroglandular tissue shows normal architecture and echotexture.

Pre and retromammary regions are unremarkable.

No obvious cyst, mass or architectural distortion visualized.

Axillary lymphnodes are not significantly enlarged and their hilar shadows are preserved.

IMPRESSION: No abnormality detected.

DR NEERA MEHTA MBBS, DMRD RMCNO.005807/14853





PATIENT NAME: AMRITA SINGH

CODE/NAME & ADDRESS : C000049066

AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN-AAKRITI LABS PVT LTD, A-430, AGRASEN MARG

JAIPUR 302017 9314660100 ACCESSION NO : 0251XB000701

PATIENT ID : FH.11704810
GLIENT PATIENT ID: 012402090021

ABHA NO :

AGE/SEX :47 Years Female DRAWN :09/02/2024 09:12:00 RECEIVED :09/02/2024 10:37:37

REPORTED :11/02/2024 15:57:14

Test Report Status	Final	Results	Biological Reference	ce Interval	Units
Lane Deferre Comment		NO CONTRACTOR OF	biological Kerereni	se interval	50000

HAEMATOLOGY - CBC								
MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE								
BLOOD COUNTS,EDTA WHOLE BLOOD								
HEMOGLOBIN (HB) METHOD: CVANIDE FREE DETERMINATION	12.2	12.0 - 15.0	g/dL					
RED BLOOD CELL (RBC) COUNT METHOD : ELECTRICAL IMPEDANCE	4.12	3.8 - 4.8	mil/µL					
WHITE BLOOD CELL (WBC) COUNT METHOD : ELECTRICAL IMPEDANCE	5.80	4.0 - 10.0	thou/µL					
PLATELET COUNT METHOD: ELECTRONIC IMPEDANCE	155	150 - 410	thou/µL					
RBC AND PLATELET INDICES		20.00	0.1					
HEMATOCRIT (PCV) METHOD: CALCULATED PARAMETER	38.2	36 - 46	%					
MEAN CORPUSCULAR VOLUME (MCV)	93.0	83 - 101	rL.					
MEAN CORPUSCULAR HEMOGLOBIN (MCH) METHOD: CALCULATED PARAMETER	29.7	27.0 - 32.0	Pg					
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC) NETHOD: CALCULATED PARAMETER	32.1	31.5 - 34.5	g/dL					
RED CELL DISTRIBUTION WIDTH (RDW) METHOD: CALCULATED PARAMETER	13.7	11.6 - 14.0	96					
MENTZER INDEX	22.6							
MEAN PLATELET VOLUME (MPV) 11.5 High 6.8 - 10.9 fL METHOD: CALCULATED PARAMETER								
WBC DIFFERENTIAL COUNT								
NEUTROPHILS METHOD: IMPEDIANCE WITH HYDRO FOCUS AND MICROSCOPY	53	40 - 80	96					
LYMPHOCYTES METHOD: IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY	40	20 - 40	%					
MONOCYTES	03	2 - 10	%					

Dr. Akansha Jain Consultant Pathologist





Page 1 Of 21

View Details

View Report









REF. DOCTOR: SELF PATIENT NAME: AMRITA SINGH

CODE/NAME & ADDRESS : C000049066

AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN-AAKRITI LABS PVT LTD, A-430, AGRASEN MARG

JAIPUR 302017 9314660100

ACCESSION NO: 0251XB000701 PATIENT ID : FH.11704810 CLIENT PATIENT ID: 012402090021

ABHA NO

AGE/SEX :47 Years Female DRAWN :09/02/2024 09:12:00 RECEIVED: 09/02/2024 10:37:37 REPORTED :11/02/2024 15:57:14

Test Report Status <u>Final</u>	Results	Biological Reference In	nterval Units
METHOD: IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY			
EOSINOPHILS METHOD: IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY	04	1 - 6	96
BASOPHILS	00	0 - 2	96
METHOD: IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY ABSOLUTE NEUTROPHIL COUNT METHOD: CALCULATED PARAMETER	3.07	2.0 - 7.0	thou/µL
ABSOLUTE LYMPHOCYTE COUNT METHOD: CALCULATED PARAMETER	2.32	1.0 - 3.0	thou/µL
ABSOLUTE MONOCYTE COUNT NETHOD: CALCULATED PARAMETER	0.17 Low	0.2 - 1.0	thou/µL
ABSOLUTE EOSINOPHIL COUNT METHOD : CALCULATED PARAMETER	0.23	0.02 - 0.50	thou/µL
ABSOLUTE BASOPHIL COUNT	0 Low	0.02 - 0.10	thou/µL
NEUTROPHIL LYMPHOCYTE RATIO (NLR)	1.3		

Interpretation(s)
BLOOD COUNTS, BDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. Howeverafter 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology. RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool **O differentiats cases of iron deficiency anaemia(> 13) from Beta thalassaemia trait

(<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for

diagnosing a case of beta thelassaemia trait.

WBC community. COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms textuage from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By concress, when age < 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By concress, when age < 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By concress, when age < 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe.

3.3, COVID-19 patients tend to show mild disease.
(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients ; A.-P. Yang, et al.; International Immunopharmacology 84 (2020) 106504.
This ratio element is a calculated parameter and out of NABL scope.

Dr. Akansha Jain Consultant Pathologist Page 2 Of 21













PATIENT NAME: AMRITA SINGH

CODE/NAME & ADDRESS : C000049066

AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN-AAKRITI LABS PVT LTD, A-430, AGRASEN MARG

JAIPUR 302017 9314660100 ACCESSION NO: 0251XB000701

PATIENT ID : FH.11704810

CLIENT PATIENT ID: 012402090021

ABHA NO

AGE/SEX :47 Years Female DRAWN :09/02/2024 09:12:00

RECEIVED :09/02/2024 10:37:37 REPORTED :11/02/2024 15:57:14

Test Report Status Final Results Biological Reference Interval Units

HAEMATOLOGY

MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE

GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE

BLOOD

HBA1C 4.1

Non-diabetic: < 5.7 Pre-diabetics: 5.7 - 6.4 Diabetics: > or = 6.5 Therapeutic goals: < 7.0 Action suggested : > 8.0 (ADA Guideline 2021)

METHOD: HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC)

ESTIMATED AVERAGE GLUCOSE(EAG)

METHOD: CALCULATED PARAMETER

71.0 < 116.0

mg/dL

96

Dr. Akansha Jain Consultant Pathologist

Page 3 Of 21





View Details

View Report







CODE/NAME & ADDRESS : C000049066

AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN-AAKRITI LABS PVT LTD, A-430, AGRASEN MARG

1AIPUR 302017 9314660100

ACCESSION NO: 0251XB000701

PATIENT ID: : FH.11704810 CLIENT PATIENT ID: 012402090021

ABHA NO

AGE/SEX :47 Years Eemale DRAWN :09/02/2024 09:12:00

RECEIVED: 09/02/2024 10:37:37 REPORTED :11/02/2024 15:57:14

Test Report Status Final Results Biological Reference Interval Units

MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE

ERYTHROCYTE SEDIMENTATION RATE (ESR), EDTA BLOOD

mm at 1 hr E.S.R. 0 - 20

METHOD: AUTOMATED (PHOTOMETRICAL CAPILLARY STOPPED FLOW KINETIC ANALYSIS)*

Interpretation(s) GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-Used For:

- 1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.
- 2. Diagnosing diabetes
- 3. Identifying patients at increased risk for diabetes (prediabetes).

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic petients, and 2 times per year for well-controlled "type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range.

1. ANG (Estimated average glucose) converts percentage HbA1c to ms/dl, to compare blood glucose levels.

2. ANG glyes an evaluation of blood glucose levels for the last couple of months.

3. ANG is calculated as ANG (mg/dl) = 28.7 " HbA1c - 46.7

HbA1c Estimation can get affected due to:

- Shortened Brythrocyte survival: Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acuta blood loss, hemolytic
- 1. Snottened a provincyte survival : Any condition tract snottened survival of access mean enymocyte age (e.g. recovery from access glood loss, nemo you anemia) will falsely lower that it this results. Fructosamine is recommended in these patterns which indicates diabetes control over 15 days.

 2. Vitamin C & E are reported to falsely lower test results. (possibly by inhibiting glycation of hemoglobin.

 3. Iron deficiency anemia is reported to interfere with some assay methods, falsely increasing results.

 4. Interference of hemoglobinopathies in HbA1c estimation to seem in
- a) Homozygous hemoglobinopathy, Pructosiamine is recommended for testing of HbA1c.
 b) Heterozygous state detected (D10 is corrected for Hb5 & HbC trait.)
- c) HbF > 25% on alternate patform (Boronate affinity chromatography) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy ERYTHROCYTE SEDIMENTATION RATE (ESR),EDTA BLOOD-TEST DESCRIPTION:

Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of crythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowedays fully automated instruments are available to measure ESR.

ESR is not diagnostic; it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change.

TEST INTERPRETATION Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia. Halignancies and plasma cell dyscrasias, Acute allergy Tissue Injury, Pregnancy,

Estrogen medication, Aging, Finding a very accelerated ESR(>100 mm/hour) in petients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias,

Disseminated malignancies, connective tissuedisease, severe infections such as bacterial endocarditis).

In pregnancy BPE in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum. Decreased in: Polycythermia vera, Sickle cell anemia

False elevated ESR: Increased fibrinogen, Drugs(Vitamin A, Dextran etc.), Hypercholesterolemia
False Decreased: Polikilocytosis, (SickleCells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs(Quinine, salicylates)

REFERENCE:
1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition; 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin; 3. The reference for the adult reference range is "Practical Haematology by Dade and Lewis, 10th edition."

Dr. Akansha Jain Consultant Pathologist Page 4 Of 21





PERFORMED AT :





REF. DOCTOR: SELF PATIENT NAME: AMRITA SINGH

CODE/NAME & ADDRESS : C000049066

AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN-AAKRITI LABS PVT LTD, A-430, AGRASEN MARG

1AIPUR 302017 9314660100

ACCESSION NO: 0251XB000701

PATIENT ID : FH.11704810 CLIENT PATIENT ID: 012402090021

ABHA NO

AGE/SEX :47 Years Female DRAWN :09/02/2024 09:12:00

RECEIVED: 09/02/2024 10:37:37 REPORTED :11/02/2024 15:57:14

Test Report Status Final Results Biological Reference Interval Units

IMMUNOHAEMATOLOGY

MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD

ABO GROUP TYPE B

METHOD: TUBE AGGLUTINATION

RH TYPE POSITIVE

METHOD: TUBE AGGLUTINATION

Interpretation(s)
ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-Blood group is identified byantigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or Ab.

Disclaimer: "Please note, as the results of previous ABO and Rhigroup (Blood Group) for pregnant women are not available, please check with the patient records for

The bask is performed by both forward as well as reverse grouping methods.

Dr. Akansha Jain **Consultant Pathologist** Page 5 Of 21













PATIENT NAME: AMRITA SINGH

CODE/NAME & ADDRESS : C000049066

AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN-AAKRITI LABS PVT LTD, A-430, AGRASEN MARG

JAJPUR 302017 9314660100

ACCESSION NO: 0251XB000701

PATIENT ID : FH.11704810 CLIENT PATIENT ID: 012402090021

ABHA NO

AGE/SEX :47 Years Female DRAWN :09/02/2024 09:12:00

RECEIVED: 09/02/2024 10:37:37 REPORTED :11/02/2024 15:57:14

Test Report Status Final Results Biological Reference Interval Units

BIOCHEMISTRY

MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE

GLUCOSE FASTING, FLUORIDE PLASMA


FBS (FASTING BLOOD SUGAR)

90

74 - 99

mg/dL

METHOD: GLUCOSE OXIDASE



GLUCOSE, POST-PRANDIAL, PLASMA

PPBS(POST PRANDIAL BLOOD SUGAR)

METHOD: GLUCOSE OXIDASE

102

70 - 140

mg/dL

Dr. Akansha Jain **Consultant Pathologist** Page 6 Of 21













Units

PATIENT NAME: AMRITA SINGH

CODE/NAME & ADDRESS : C000049066
AGILUS DIAGNOSTICS LIMITED-WEL WALK-INAAKRITI LABS PVT LTD. A-430, AGRASEN MARG

Final

JAIPUR 302017 9314660100

Test Report Status

ACCESSION NO : 0251XB000701

PATIENT ID : FH.11704810

CLIENT PATIENT ID: 012402090021


ABHA NO :

Results


AGE/SEX :47 Years Female DRAWN :09/02/2024 09:12:00 RECEIVED :09/02/2024 10:37:37 REPORTED :11/02/2024 15:57:14

Biological Reference Interval

REF. DOCTOR: SELF



CHOLESTEROL, TOTAL 128 < 200 Desirable mg/dL 200 - 239 Borderline High >/= 240 High METHOD: CHOLESTEROL OXIDASE mg/dL TRIGLYCERIDES 75 < 150 Normal 150 - 199 Borderline High 200 - 499 High >/=500 Very High METHOD: LIPASE/GPO-PAP NO CORRECTION HDL CHOLESTEROL 43 < 40 Low mg/dL >/=60 High METHOD: DIRECT CLEARANCE METHOD < 100 Optimal mg/dL 70 CHOLESTEROL LDL 100 - 129 Near optimal/ above optimal 130 - 159 Borderline High 160 - 189 High >/= 190 Very High





Page 7 Of 21

View Details

View Report










CODE/NAME & ADDRESS : C000049066
AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN-

AAKRITI LABS PVT LTD, A-430, AGRASEN MARG JAIPUR 302017 9314660100 ACCESSION NO: 0251XB000701
PATIENT ID: FH.11704810
CLIENT PATIENT ID: 012402090021

ABHA NO :

AGE/SEX :47 Years Female DRAWN :09/02/2024 09:12:00 RECEIVED :09/02/2024 10:37:37 REPORTED :11/02/2024 15:57:14

Test Report Status <u>Final</u>	Results	Biological Reference Interval Units
NON HDL CHOLESTEROL	85	Desirable: Less than 130 mg/dL Above Desirable: 130 - 159 Borderline High: 160 - 189 High: 190 - 219 Very high: > or = 220
METHOD: CALCULATED PARAMETER VERY LOW DENSITY LIPOPROTEIN	15.0	√ (= 30.0 ma/d)
AEKI TOM DENZILI TILOHKO IETIA	15.0	= 30.0 mg/dL</td
CHOL/HDL RATIO	3.0 Low	3.3 - 4.4 Low Risk 4.5 - 7.0 Average Risk 7.1 - 11.0 Moderate Risk > 11.0
LDL/HDL RATIO	1.6	High Risk 0.5 - 3.0 Desirable/Low Risk 3.1 - 6.0 Borderline/Moderate Risk >6.0 High Risk



Dr. Akansha Jain Consultant Pathologist Page 8 Of 21





View Details

View Benort











CODE/NAME & ADDRESS : C000049066
AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN-AAKRITI LABS PVT LTD, A-430, AGRASEN MARG

JAIPUR 302017 9314660100 ACCESSION NO: 0251XB000701 PATIENT ID: FH.11704810

CLIENT PATIENT ID: 012402090021 ABHA NO : AGE/SEX :47 Years Female DRAWN :09/02/2024 09:12:00 RECEIVED :09/02/2024 10:37:37 REPORTED :11/02/2024 15:57:14

Test Report Status Final Results Biological Reference Interval Units





Interpretation(s)

Dr. Akansha Jain Consultant Pathologist Page 9 Of 21





View Details

View Report











REF. DOCTOR: SELF **PATIENT NAME: AMRITA SINGH**

CODE/NAME & ADDRESS : C000049066 AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN-AAKRITI LABS PVT LTD, A-430, AGRASEN MARG

JAIPUR 302017 9314660100

ACCESSION NO: 0251XB000701 PATIENT ID : FH.11704810 CLIENT PATIENT ID: 012402090021

ABHA NO

:47 Years AGE/SEX Female DRAWN :09/02/2024 09:12:00 RECEIVED: 09/02/2024 10:37:37

REPORTED :11/02/2024 15:57:14

Test Report Status Final Results Biological Reference Interval Units

Serum lipid profile is measured for cardiovascular risk prediction. Lipid Association of India recommends LDL-C as primary target and Non HDL-C as co-primary treatment target.

Risk Stratification for ASCVD (Atherosclerotic cardiovascular disease) by Lipid Association of India

Risk Category						
Extreme risk group	A.CAD with > 1 feature of high risk group					
	B. CAD with > 1 feature of Very high risk g	roup or recurrent ACS (within 1 year) despite LDL-C < or =				
	50 mg/dl or polyvascular disease					
Very High Risk	 Established ASCVD 2. Diabetes with 2 r 	najor risk factors or evidence of end organ damage 3.				
	Familial Homozygous Hypercholesterolemi	1				
High Risk	Three major ASCVD risk factors. 2. Diabetes with 1 major risk factor or no evidence of end organ					
		90 mg/dl 5. Extreme of a single risk factor. 6. Coronary				
	Artery Calcium - CAC >300 AU. 7. Lipopr	otein a >/= 50mg/dl 8. Non stenotic carotid plaque				
Moderate Risk	2 major ASCVD risk factors					
Low Risk	0-1 major ASCVD risk factors					
Major ASCVD (Ath	erosclerotic cardiovascular disease) Risk Fa	ctors				
1. Age > or = 45 year	1. Age > or = 45 years in males and > or = 55 years in females 3. Current Cigarette smoking or tobacco use					
2. Family history of p	remature ASCVD	4. High blood pressure				
5. Low HDL						

Newer treatment goals and statin initiation thresholds based on the risk categories proposed by LAI in 2020.

Risk Group	Treatment Goals		Consider Drug Therapy	
	LDL-C (mg/dl)	Non-HDL (mg/dl)	LDL-C (mg/dl)	Non-HDL (mg/dl)
Extreme Risk Group Category A	<50 (Optional goal	< 80 (Optional goal	>OR = 50	>OR = 80
	< OR = 30)	<or 60)<="" =="" td=""><td></td><td></td></or>		
Extreme Risk Group Category B	<or 30<="" =="" td=""><td><or 60<="" =="" td=""><td>> 30</td><td>>60</td></or></td></or>	<or 60<="" =="" td=""><td>> 30</td><td>>60</td></or>	> 30	>60
Very High Risk	<50	<80	>OR= 50	>OR= 80
High Risk	<70	<100	>OR= 70	>OR= 100
Moderate Risk	<100	<130	>OR= 100	>OR= 130
Low Risk	<100	<130	>OR= 130*	>OR= 160

^{*}After an adequate non-pharmacological intervention for at least 3 months.

References: Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India. Current Vascular Pharmacology, 2022, 20, 134-155.

LIVER FUNCTION PROFILE, SERUM

0.68	0 - 1	mg/dL
0.26 High	0.00 - 0.25	mg/dL
0.42	0.1 - 1.0	mg/dL
7.8	6.4 - 8.2	g/dL
4.4	3.8 - 4.4	g/dL
	0.26 High 0.42 7.8	0.26 High 0.00 - 0.25 0.42 0.1 - 1.0 7.8 6.4 - 8.2

METHOD: BROMOCRESOL GREEN

Dr. Akansha Jain **Consultant Pathologist** Page 10 Of 21













PATIENT NAME: AMRITA SINGH

CODE/NAME & ADDRESS : C000049066

AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN-AAKRITI LABS PVT LTD, A-430, AGRASEN MARG

JAJPUR 302017 9314660100


ACCESSION NO: 0251XB000701

PATIENT ID : FH.11704810 CLIENT PATIENT ID: 012402090021

ABHA NO

AGE/SEX Female :47 Years DRAWN :09/02/2024 09:12:00 RECEIVED: 09/02/2024 10:37:37 REPORTED :11/02/2024 15:57:14

	j 		
Test Report Status <u>Final</u>	Results	Biological Reference In	terval Units
GLOBULIN	3.4	2.0 - 4.1	g/dL
METHOD: CALCULATED PARAMETER			
ALBUMIN/GLOBULIN RATIO	1.3	1.0 - 2.1	RATIO
METHOD: CALCULATED PARAMETER			
ASPARTATE AMINOTRANSFERASE(AST/SGOT)	27	0 - 31	U/L
METHOD: TRIS BUFFER NO PSP IFOC / SFBC 37° C			
ALANINE AMINOTRANSFERASE (ALT/SGPT)	19	0 - 31	U/L
METHOD: TRIS BUFFER NO PSP IFCC / SPBC 37° C			
ALKALINE PHOSPHATASE	142 High	39 - 117	U/L
METHOD: AMP OPTIMISED TO IFCC 37° C	_		
GAMMA GLUTAMYL TRANSFERASE (GGT)	9	7 - 32	U/L
METHOD: GAMMA GLUTAMYL-3 CARBOXY-4 NITROANILIDE (IFCC)	37° C		
LACTATE DEHYDROGENASE	306	230 - 460	U/L
BLOOD UREA NITROGEN (BUN), SERUM			
BLOOD UREA NITROGEN	9	5.0 - 18.0	mg/dL
METHOD: UREASE KINETIC			



CREATININE, SERUM

Dr. Akansha Jain **Consultant Pathologist** Page 11 Of 21













PATIENT NAME: AMRITA SINGH

CODE/NAME & ADDRESS : C000049066
AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN-AAKRITI LABS PVT LTD, A-430, AGRASEN MARG

JAIPUR 302017 9314660100 REF. DOCTOR : SELF ACCESSION NO : 0251XB000701 AGE

PATIENT ID : FH.11704810 CLIENT PATIENT ID: 012402090021

ABHA NO :


AGE/SEX :47 Years Female DRAWN :09/02/2024 09:12:00 RECEIVED :09/02/2024 10:37:37

REPORTED :11/02/2024 15:57:14

Test Report Status	Einal	Results Bio	ological Reference Interval	Unite
rest keport status	-inai	Results Bio	ological Kererence Interval	Unites

CREATININE 0.71 0.6 - 1.2 mg/dL

METHOD: ALKALINE PICRATE NO DEPROTEINIZATION



BUN/CREAT RATIO

BUN/CREAT RATIO 12.68

METHOD: CALCULATED PARAMETER.

URIC ACID, SERUM

URIC ACID 4.1 2.4 - 5.7 mg/dL

METHOD: URICASE PEROXIDASE WITH ASCORBATE OXIDASE

 TOTAL PROTEIN, SERUM

 TOTAL PROTEIN
 7.8
 6.4 - 8.3
 g/dL

METHOD: BIURET REACTION, END POINT

ALBUMIN, SERUM

ALBUMIN 4.4 3.8 - 4.4 g/dL

Dr. Akansha Jain Consultant Pathologist



Page 12 Of 21

View Details

View Benort









CODE/NAME & ADDRESS : C000049066
AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN-AAKRITI LABS PVT LTD, A-430, AGRASEN MARG

JAIPUR 302017 9314660100 ACCESSION NO: 0251XB000701
PATIENT ID: FH.11704810
CLIENT PATIENT ID: 012402090021

ABHA NO :

AGE/SEX :47 Years Female DRAWN :09/02/2024 09:12:00 RECEIVED :09/02/2024 10:37:37 REPORTED :11/02/2024 15:57:14

I .				
Test Report Status	Final	Results	Biological Reference Interval	Umits
I TRUE INTERNAL CANALIS	FILLERI	PERSONAL PROP	Biological Kererence Interval	548.0

METHOD: BROMOCRESOL GREEN

GLOBULIN

GLOBULIN 3.4 2.0 - 4.1 g/dL

ELECTROLYTES (NA/K/CL), SERUM

METHOD: ION-SELECTIVE ELECTRODE

Interpretation(s)

Sodium	Potassium	Chloride
Decreased in: CCF, cirrhosis, vomiting, diarrhea, excessive sweating, sait-losing nephropathy, adrenal insufficiency, nephrotic syndrome, water intoxication, SIADH, Drugs: thiazides, diuretics, ACE inhibitors, chlorpropamide, carbamazepine, anti depressants (SSRI), antipsychotics.	Decreased in: Low potassium intake, profonged vomiting or diarrhea, RIA types I amo II, hyperaldosteronism, Cushing's syndrome, osmotic diuresis (e.g., hyperglycemia), alkalosis, familial periodic paralysis, trauma (transient). Drugs: Adrenergic agents, diuretics.	Decreased in: Vomiting, diarrhua, renal failure combined with self deprivation, over-treatment with diuretics, chronic respiratory ecidosis, diabetic ketoacidosis, excessive sweating, SIADH, salt-losing nephropathy, porphyria, expansion of extracellular fluid volume, adrenalinsufficiency, hyperaldosteronism, metabolic alkalosis. Drugs: chronic laxative, corticosteroids, diuretics.
Increased in: Dehydration (excessivesweating, severe vomiting or diarrhea), diabetes mellitus, diabetesinsipidus, hyperaldosteronism, inadequate water intake. Drugs: steroids, licorice, oral contraceptives.	Increased in: Massive hemolysis, severe tissue damage, rhabdomyolysis, acidosis, dehydration, renal failure, Addison's disease, RTA type JV, hyperkalemic familial periodic paralysis. Drugs: potassium salts, potassium-sparing diuretics, MSAIDs, beta-blockers, ACE inhibitors, highdose trimethoprim-sulfamethoxazole.	Increased in: Renal failure, rephrotic syndrome, RTA, dehydration, overtreatment with saline, hyperparathyroidism, diabetes insipidus, metabolic acidosis from diarrhea (Loss of HCO3-), respiratory alkalosis, hyperadrenocorticism. Drugs: acetazolamide, androgens, hydrochlorothiazide, salicylates.
Interferences: Severe lipemia or hyperproteinemi, if sodium analysis involves a dilution step can cause spurious results. The serum sodium falls about 1.6 mEq/L for each 100 mg/dL increase in blood glucose.	Interferences: Hemolysis of sample, delayed separation of serum, prolonged fist clenching during blood drawing, and prolonged tourniquet placement. Very high WBC/PLT counts may cause spurious. Plasma potassium levels are normal.	Interferences:Test is helpful in assessing normal and increased anion gap metabolic acidosis and in distinguishing hypercalcemia due to hyperparathyroidism (high serum chloride) from that due to malignancy (Normal serum chloride)

Dr. Akansha Jain Consultant Pathologist Page 13 Of 21





View Details

View Benort









CODE/NAME & ADDRESS : C000049066

AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN-AAKRITI LABS PVT LTD, A-430, AGRASEN MARG

1AIPUR 302017 9314660100

ACCESSION NO: 0251XB000701 PATIENT ID : FH.11704810 CLIENT PATIENT ID: 012402090021

ABHA NO

AGE/SEX :47 Years Female DRAWN :09/02/2024 09:12:00 RECEIVED: 09/02/2024 10:37:37

REPORTED :11/02/2024 15:57:14

Test Report Status Final Results Biological Reference Interval Units

Interpretation(s)
OLUCOSE FASTING/FLUORIDE PLASMA-TEST DESCRIPTION

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to hissues and sothat no glucose is excreted in the

Increased in:Diabetes mellitus, Cushing's syndrome (10 - 15%), chronic pancreatitis (30%). Drugs:corticosteroids.phenytoin, estrogen, thiazides.

Decreased in:Pancreatic islet cell disease with increased insulin,insulinoma,adrenocortical insufficiency,hypopituitarism,diffuse liver disease,

malignancy(adrenocortical,stomach,fibrosarcoma),infant of a diabetic mother,enzyme deficiency

ses(e.g.galactosemia),Drugs-insulin,ethanol,propranolol;sulfonylureas,tolbutamide,and other oral hypoglycemic #9##15

ASSESSED AND SET PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level as the factuation within and the product of the pr

treatment, Renal Glycouria, Glycaemic Index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & enertivity etc.Additional test HAAIc LIVER FUNCTION PROFILE, SERUMBillrubin is a yellowish plyment found in bile and is a breakflown product of normal heme catabolism. Billrubin is excreted in bile and unine, and elevated levels may give yellow discoloration ju journduce. Elevated levels results from increased billrubin production (eg., hemolysis and ineffective enythropoissis), decreased billrubin excretion (eg., obstruction and hepatibis), and abnormal billrubin metabolism (eg., hereditary and neonatal joundice). Conjugated (direct) billrubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts. Ike in Gallstones getting into the bile ducts, turnors & Scarring of the bile ducts, Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious animia. Transfusion reaction 8 a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that

may be a result of resmoyed or permous are may, managed the supermodule of common managed control various parts of the body. AST in found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and R in commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepotitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attackor stremuous activity. ALT their measures the amount of this enzyme in the blood. ALT is found mainly in the liver, but also insmaller amounts in the kidneys, heart, muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health. AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis, obstruction of bile ducts, cimhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Billary obstruction, Osteoblastic bone turnorii, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Pagets disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hyperparathyroidism, Pagets disease, Pickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hyperparathyroidism, Pagets disease, Pickets, Sarcoidosis etc.

In thysophosphatexis, Mainutrition, Protein deficiency, Wilsons alsoises.

GGT is an enzyme found in cell membranes of manytissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, billiary system and pencreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc.

Total Protein also known as total protein; is a blochemical Mais for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HEV and hepatitis Ellips C, Multiplie myeloma, Walderstroms disease. Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Mainutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

Albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hyposibuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased kumphatic dearrance malnutrition and westing etc.

[hyposibuminemia] can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphotic dearance, mainutrition and wasting etc.

BLOCO URLEA NITROGEN (BUN), SERUM-Causes of Increased levels include Pris renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism)

Causes of decreased level include Liver disease, SIADH,

CREATININE, SERUM-Higher than normal level may be due to:

Blockage in the urinary tract, Kidney proteins, such as kidney damage of failure, infection, or reduced blood flow, Loss of body fluid (dehydration), Muscle problems, such as breakdown of muscle fibers, Problems during pregnancy, such as setzures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia)

Lower than normal level may be due to: Physotheria Gravis, Muscleophy

URIC ACID, SERUM-Causes of Increased levels-Low Zinc intake, OCP, Multiple Sclerosis

TOTAL PROTEIN, SERUM-to a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin.

Higher-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Mainutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Mainutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

Lower-than-normal levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, etc.

protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liverdisease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropethy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, mainutrition and wasting etc.

Dr. Akansha Jain Consultant Pathologist Page 14 Of 21













CODE/NAME & ADDRESS : C000049066

AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN-AAKRITI LABS PVT LTD, A-430, AGRASEN MARG

JAIPUR 302017 9314660100 ACCESSION NO: 0251XB000701 PATIENT ID : FH.11704810

CLIENT PATIENT ID: 012402090021

ABHA NO

AGE/SEX :47 Years Female DRAWN :09/02/2024 09:12:00 RECEIVED :09/02/2024 10:37:37

REPORTED :11/02/2024 15:57:14

Test Report Status Final Results Biological Reference Interval Units

CLINICAL PATH - URINALYSIS

MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE

PHYSICAL EXAMINATION, URINE

COLOR PALE YELLOW

METHOD: GROSS EXAMINATION

APPEARANCE CLEAR

METHOD: GROSS EXAMINATION

CHEMICAL EXAMINATION, URINE

PH 6.5 4.7 - 7.5

METHOD: DOUBLE INDICATOR PRINCIPLE
SPECIFIC GRAVITY 1.010 1.003 - 1.035

METHOD: IONIC CONCENTRATION METHOD

PROTEIN NOT DETECTED NEGATIVE

METHOD: PROTEIN ERROR OF INDICATORS WITH REFLECTANCE

GLUCOSE NOT DETECTED NEGATIVE

METHOD: GLUCOSE OXIDASE PEROXIDASE / BENEDICTS

KETONES NOT DETECTED NOT DETECTED

METHOD: SODIUM NITROPRUSSIDE REACTION

BLOOD NOT DETECTED NEGATIVE METHOD: PEROCIDASE ANTI PEROXIDASE

BILIRUBIN NOT DETECTED NOT DETECTED

METHOD : DIPSTICK
UROBILINOGEN NORMAL NORMAL

METHOD : EHRLICH REACTION REPLECTANCE

NITRITE NOT DETECTED NOT DETECTED

METHOD: NITRATE TO NITRITE CONVERSION METHOD

LEUKOCYTE ESTERASE NOT DETECTED NOT DETECTED

MICROSCOPIC EXAMINATION, URINE

RED BLOOD CELLS NOT DETECTED NOT DETECTED /HPF

METHOD: MICROSCOPIC EXAMINATION
PUS CELL (WBC'S) 2-3 0-5 /HPF

METHOD: DIPSTICK, MICROSCOPY

Dr. Akansha Jain Consultant Pathologist Page 15 Of 21





View Details

View Benort









CODE/NAME & ADDRESS : C000049066
AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN-AAKRITI LABS PVT LTD, A-430, AGRASEN MARG

JAIPUR 302017 9314660100 ACCESSION NO: 0251XB000701
PATIENT ID: FH.11704810
CLIENT PATIENT ID: 012402090021

ABHA NO :

AGE/SEX :47 Years Female DRAWN :09/02/2024 09:12:00 RECEIVED :09/02/2024 10:37:37 REPORTED :11/02/2024 15:57:14

Test Report Status <u>Final</u>	Results	Biological Reference	Interval Units
EPITHELIAL CELLS METHOD: MICROSCOPIC EXAMINATION	3-5	0-5	/HPF
CASTS	NOT DETECTED		
METHOD: MICROSCOPIC EXAMINATION CRYSTALS METHOD: MICROSCOPIC EXAMINATION	NOT DETECTED		
BACTERIA	NOT DETECTED	NOT DETECTED	
METHOD: MICROSCOPIC EXAMINATION YEAST	NOT DETECTED	NOT DETECTED	

Interpretation(s)

The following table describes the probable conditions, in which the analytes are present in urine

Presence of	Conditions			
Proteins	Inflammation or immune illnesses			
Pus (White Blood Cells)	Urinary tract infection, urinary tract or kidney stone, tumors or any kind of kidney impairment			
Glucose	Diabetes or kidney disease			
Ketones	Diabetic ketoacidosis (DKA), starvation or thirst			
Urobilinogen	Liver disease such as hepatitis or cirrhosis			
Blood	Renal or genital disorders/trauma			
Bilirubin	Liver disease			
Erythrocytes	Urological diseases (e.g. kidney and bladder cancer, urolithiasis), urinary tract infection and glomerular diseases			
Leukocytes	Urinary tract infection, glomerulonephritis, interstitial nephritis either acute or chronic, polycystic kidney disease, urolithiasis, contamination by genital secretions			
Epithelial cells	Urolithiasis, bladder carcinoma or hydronephrosis, ureteric stents or bladder catheters for prolonged periods of time			
Granular Casts	Low intratubular pH, high urine osmolality and sodium concentration, interaction with Bence-Jones protein			
Hyaline casts	Physical stress, fever, dehydration, acute congestive heart failure, renal diseases			

Dr. Akansha Jain Consultant Pathologist Page 16 Of 21







View Report









CODE/NAME & ADDRESS : C000049066
AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN-AAKRITI LABS PVT LTD, A-430, AGRASEN MARG

JAIPUR 302017 9314660100 ACCESSION NO: 0251XB000701
PATIENT ID: FH.11704810
CLIENT PATIENT ID: 012402090021

ABHA NO :

AGE/SEX :47 Years Fernale DRAWN :09/02/2024 09:12:00 RECEIVED :09/02/2024 10:37:37

REPORTED :11/02/2024 15:57:14

Test Report Status Final Results Biological Reference Interval Units

Calcium oxalate	Metabolic stone disease, primary or secondary hyperoxaluria, intravenous infusion of large doses of vitamin C, the use of vasodilator naftidrofuryl oxalate or the gastrointestinal lipase inhibitor orlistat, ingestion of ethylene glycol or of star fruit (Averrhoa carambola) or its juice		
Uric acid	arthritis		
Bacteria	Urinary infectionwhen present in significant numbers & with pus cells.		
Trichomonas vaginalis	Vaginitis, cervicitis or salpingitis		

Dr. Akansha Jain Consultant Pathologist



Page 17 Of 21

View Details

View Report









PATIENT NAME: AMRITA SINGH

CODE/NAME & ADDRESS : C000049066

AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN-AAKRITI LABS PVT LTD, A-430, AGRASEN MARG

JAIPUR 302017 9314660100 ACCESSION NO : 0251XB000701

PATIENT ID : FH.11704810

CLIENT PATIENT ID: 012402090021

ABHA NO

AGE/SEX :47 Years Female DRAWN :09/02/2024 09:12:00

RECEIVED : 09/02/2024 10:37:37 REPORTED :11/02/2024 15:57:14

Test Report Status Final Results Biological Reference Interval Units

CYTOLOGY

MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE

PAPANICOLAOU SMEAR

TEST METHOD SAMPLE NOT RECEIVED

Dr. Akansha Jain Consultant Pathologist



Page 18 Of 21

View Details

View Report









PATIENT NAME: AMRITA SINGH

CODE/NAME & ADDRESS : C000049066
AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN-AAKRITI LABS PVT LTD, A-430, AGRASEN MARG

JAIPUR 302017 9314660100 REF. DOCTOR : SELF
ACCESSION NO: 0251XB000701 AGE

PATIENT ID : FH.11704810 CLIENT PATIENT ID: 012402090021

ABHA NO

AGE/SEX :47 Years Female DRAWN :09/02/2024 09:12:00

RECEIVED :09/02/2024 10:37:37 REPORTED :11/02/2024 15:57:14

Test Report Status Final Results Biological Reference Interval Units

CLINICAL PATH - STOOL ANALYSIS

MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE

PHYSICAL EXAMINATION, STOOL

COLOUR SAMPLE NOT RECEIVED

METHOD: GROSS EXAMINATION

Dr. Abhishek Sharma Consultant Microbiologist

Page 19 Of 21





View Details

View Report







0.550 - 4.780



PATIENT NAME: AMRITA SINGH REF. DOCTOR: SELF

CODE/NAME & ADDRESS : C000049066
AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN-AAKRITI LABS PVT LTD, A-430, AGRASEN MARG

JAIPUR 302017 9314660100 ACCESSION NO: 0251XB000701 PATIENT ID : FH.11704810

CLIENT PATIENT ID: 012402090021

ABHA NO :

AGE/SEX :47 Years Female DRAWN :09/02/2024 09:12:00 RECEIVED :09/02/2024 10:37:37

REPORTED :11/02/2024 15:57:14

Test Report Status Final Results Biological Reference Interval Units

SPECIALISED CHEMISTRY - HORMONE

MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE

THYROID PANEL, SERUM

T3 128.10 60.0 - 181.0 ng/dL

METHOD: CHEMILUMINESCENCE

Γ4 **11.10 High** 4.5 - 10.9 μg/dL

METHOD: CHEMILUMINESCENCE TSH (ULTRASENSITIVE) METHOD: CHEMILUMINESCENCE

1.163

μIU/mL

Interpretation(s)


Triiodothyronine T3, Thyroxine T4, and Thyroid Stimulating Hormone TSH are thyroid hormones which affect almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate.

Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH.

Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism.

In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hypothyroidism, TSH levels are low. Below mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3. Measurement of the serum TT3 level is a more sensitive test for the diagnosis of hypothyroidism, and measurement of TT4 is more useful in the diagnosis of hypothyroidism. Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically active. It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.

Sr. No.	TSH	Total T4	FT4	Total T3	Possible Conditions
1	High	Low	Low	Low	(1) Primary Hypothyroidism (2) Chronic autoimmune Thyroiditis (3)
					Post Thyroidectomy (4) Post Radio-Iodine treatment
2	High	Normal	Normal	Normal	(1)Subclinical Hypothyroidism (2) Patient with insufficient thyroid
					hormone replacement therapy (3) In cases of Autoimmune/Hashimoto
					thyroiditis (4). Isolated increase in TSH levels can be due to Subclinical
					inflammation, drugs like amphetamines, Iodine containing drug and
					dopamine antagonist e.g. domperidone and other physiological reasons.
3	Normal/Low	Low	Low	Low	(1) Secondary and Tertiary Hypothyroidism
4	Low	High	High	High	(1) Primary Hyperthyroidism (Graves Disease) (2) Multinodular Goitre
					(3)Toxic Nodular Goitre (4) Thyroiditis (5) Over treatment of thyroid
					hormone (6) Drug effect e.g. Glucocorticoids, dopamine, T4
					replacement therapy (7) First trimester of Pregnancy
5	Low	Normal	Normal	Normal	(1) Subclinical Hyperthyroidism



Page 20 Of 21





View Details

View Report









CODE/NAME & ADDRESS : C000049066

AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN-AAKRITI LABS PVT LTD, A-430, AGRASEN MARG

JAIPUR 302017 9314660100 ACCESSION NO: 0251XB000701 PATIENT ID : FH.11704810

CLIENT PATIENT ID: 012402090021

00701 AGE/SEX :47 Years Female B10 DRAWN :09/02/2024 09:12:00 RECEIVED :09/02/2024 10:37:37

REPORTED :11/02/2024 15:57:14

Test Report Status <u>Final</u> Results Biological Reference Interval Units

ABHA NO

6	High	High	High	High	(1) TSH secreting pituitary adenoma (2) TRH secreting tumor
7	Low	Low	Low	Low	(1) Central Hypothyroidism (2) Euthyroid sick syndrome (3) Recent
					treatment for Hyperthyroidism
8	Normal/Low	Normal	Normal	High	(1) T3 thyrotoxicosis (2) Non-Thyroidal illness
9	Low	High	High	Normal	(1) T4 Ingestion (2) Thyroiditis (3) Interfering Anti TPO antibodies

REF: 1. TIETZ Fundamentals of Clinical chemistry 2. Guidlines of the American Thyroid association duriing pregnancy and Postpartum, 2011.

NOTE: It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.TSH is not affected by variation in thyroid - binding protein. TSH has a diurnal rhythm, with peaks at 2:00 - 4:00 a.m. And troughs at 5:00 - 6:00 p.m. With ultradian variations.

End Of Report
Please visit www.agilusdiagnostics.com for related Test Information for this accession

CONDITIONS OF LABORATORY TESTING & REPORTING

- It is presumed that the test sample belongs to the patient named or identified in the test requisition form.
- All tests are performed and reported as per the turnaround time stated in the AGILUS Directory of Services.
- Result delays could occur due to unforeseen circumstances such as non-availability of kits / equipment breakdown / natural calamities / technical downtime or any other unforeseen event.
- 4. A requested test might not be performed if:
 - i. Specimen received is insufficient or inappropriate
 - Specimen quality is unsatisfactory
 - iii. Incorrect specimen type
 - iv. Discrepancy between identification on specimen container label and test requisition form

- AGILUS Diagnostics confirms that all tests have been performed or assayed with highest quality standards, clinical safety & technical integrity.
- Laboratory results should not be interpreted in isolation; it must be correlated with clinical information and be interpreted by registered medical practitioners only to determine final diagnosis.
- Test results may vary based on time of collection, physiological condition of the patient, current medication or nutritional and dietary changes. Please consult your doctor or call us for any clarification.
- 8. Test results cannot be used for Medico legal purposes.
- In case of queries please call customer care (91115 91115) within 48 hours of the report.

Agilus Diagnostics Limited Fortis Hospital, Sector 62, Phase VIII, Mohali 160062

Dr. Akansha Jain Consultant Pathologist Page 21 Of 21





View Details

View Benort



